 |
 |
|
|
1.1. The "Wellysa" Service Terms and Conditions (hereinafter referred to as the "Terms and Conditions") document specifies the rules for the performance by NZOZ Wellysa Sp. z o.o. (hereinafter referred to as "NZOZ Wellysa") of Healthcare Services Agreements, the subject of which is the provision of health care services that constitute the Wellysa Service.
1.2. Identification data of NZOZ Wellysa Sp. z o.o. (hereinafter referred to as "NZOZ Wellysa"): Niepubliczny Zakład Opieki Zdrowia Wellysa spółka z ograniczoną odpowiedzialnością (a limited liability company) with its registered office in Warsaw at ul. Grójecka 22/24/32, 02-301 Warsaw, registered in the Register of Entrepreneurs of the National Court Register maintained by the District Court for the capital city of Warsaw in Warsaw, 12th Commercial Division of the National Court Register under KRS number 0001092700, Tax Identification Number (NIP) 5252996220, National Business Registry Number (REGON) 528027906, entered into the Register of Entities Performing Medical Activities under number 000000289562, with share capital of PLN 5,000.
1.3. NZOZ Wellysa is a subsidiary of Wellysa Spółka Akcyjna, with its registered office in Warsaw at ul. Grójecka 22/24/32, 02-301 Warsaw, entered into the Register of Entrepreneurs of the National Court Register maintained by the District Court for the capital city of Warsaw in Warsaw, 12th Commercial Division of the National Court Register, under KRS number 0000995956, Tax Identification Number (NIP) 7011112054, National Business Registry Number (REGON) 52271206, with share capital of PLN 1,677,773.02.
1.4. Email address at which the User can contact NZOZ Wellysa: [email protected]
1.5. The Terms and Conditions apply to Healthcare Services Agreements, on behalf of and for the benefit of NZOZ Wellysa, with Application Users via the Application, the subject of which is the provision of the Wellysa Service, and to the provision of the Wellysa Service to Patients with a Partner Code.
1.6. The Terms and Conditions contain references to the Privacy Policy and the use of Cookies for the "Wellysa" mobile application and the website www.wellysa.com (hereinafter referred to as the "Privacy Policy").
2.1. Application – the "Wellysa" mobile application provided by NZOZ Wellysa, enabling, in particular, Registration, use of the User account, purchase of the Wellysa Service, and access to the Report.
2.2. Personal Data – any information relating to an identified or identifiable natural person.
2.3. Medical Data – any information relating to the user's health, such as the results of surveys and diagnostic tests, personal and family medical history, DNA mutation test results, blood test results, and other information. Medical data is processed only by authorized entities.
2.4. Payment Service Provider – a payment service provider within the meaning of the Act of 19 August 2011 on Payment Services, which processes the Fees covered by the Terms and Conditions.
2.5. Account – the User's individual account in the Application, where the User has access, in particular, to information about orders placed by the User.
2.6. Partner Code – information containing a barcode or numeric code enabling one-time use of the Wellysa's Service, in particular access to a restricted section of the Application dedicated to the Wellysa's Service.
2.7. Discount Code – information containing a barcode or numeric code enabling use of a paid Wellysa's Service at a reduced price. The code may specify a percentage or amount discount, calculated from the Fee for a given Wellysa's Service. Discount Codes may be reusable or one-time, and may be valid indefinitely or for a specified period.
2.8. Laboratory – a healthcare entity operating a Collection Point, or not operating such a Point, within the meaning of Art. 2 point 1 of the Act of September 15, 2022, on Laboratory Medicine (consolidated text: Journal of Laws of 2023, item 2125), which provides healthcare services under a healthcare services agreement with NZOZ Wellysa.
2.9. Fee – the fee paid by the User immediately after ordering the Wellysa Service.
2.10. Wellysa's Partner – a collective term for all entities collaborating with NZOZ Wellysa under cooperation agreements, contracts for specific work, or agency agreements in the field of health promotion.
2.11. Wellysa's Medical Partner – a collective term for all entities collaborating with or providing medical services to NZOZ Wellysa under concluded cooperation agreements or contracts for the provision of medical services. Only an entity entered in the Register of Entities Performing Medical Activity or a Medical Specialist with a valid Professional License (PWZ) may become a Wellysa's Medical Partner.
2.12. Wellysa's Scientific Partner – a collective term for all entities collaborating with NZOZ Wellysa under concluded scientific cooperation agreements.
2.13. Privacy Policy – the document "Privacy and Cookie Policy for the "Wellysa" mobile application and the website www.wellysa.com." Accepting the terms of the privacy policy is a necessary element of creating a User account.
2.14. Collection Point – a single Laboratory location, or a location operated by an independent Wellysa's Medical Partner, where the User can submit biological material for testing as part of the Wellysa Service, during the days and hours of specified availability. A current list of Collection Points and their availability hours is available in the Application.
2.15. Wellysa's Report – a medical document from NZOZ Wellysa, transmitted as a file or a set of files, in PDF format, uploaded by authorized NZOZ Wellysa employees to the individual user account in the Application, which, depending on the scope of the purchased service, may consist of: (i) survey results, (ii) DNA test results, (iii) test results, (iv) (v) other information relevant to preventive medical care.
2.16. Registration – creating a User account, enabling further use of the Application and access to the Wellysa Service.
2.17. GDPR – Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (OJ EU L 119, 2016, p. 1, as amended).
2.18. Website – the "Wellysa" mobile application and the website www.wellysa.com jointly.
2.19. Website – the website www.wellysa.com, owned by Wellysa.
2.20. Healthcare Services Agreement – an agreement concluded with the User by NZOZ Wellysa.
2.21. Wellysa Service – a service in the field of medicine for preventive care (healthcare services within the meaning of Art. 2, Section 1, Item 10 of the Act of April 15, 2011 on Medical Activity (Journal of Laws of 2024, item 799), which includes various health services, individually or in the form of a set of services, which will be provided using the Application, and/or in the form of physical examinations, performed by medical entities authorized to provide health services, i.e. NZOZ Wellysa, the Laboratory, Sample Collection Points, and Wellysa Specialized Medical Partner Facilities, such as:
2.21.1. Collection of blood or other biological material at a Laboratory or Blood Collection Point
2.21.2. Self-collection of other material by the User, using a specialized self-collection kit received in person or by mail, and its delivery for analysis in person or by mail to the address of the Laboratory, Blood Collection Point, or Wellysa's Medical Partner specified by NZOZ Wellysa.
2.21.3. Analysis of a personal and family history questionnaire for selected diseases (hereinafter referred to as "genogram analysis")
2.21.4. Testing of biological material for DNA mutations, performed using various laboratory testing methods
2.21.5. Testing of blood or other collected biological material to determine the levels of various medical metrics
2.21.6. a possible repeat procedure, e.g., a second blood draw and re-analysis of biological material, if significant medical indications arise,
2.21.7. medical teleconsultation to discuss high medical risk and further medical recommendations,
2.21.8. preparation of a Wellysa's Report, transmitted as a PDF file in the Application, containing the results of the tests and analyses performed, medical risk assessments, recommendations for follow-up tests, and lifestyle changes.
2.21.9. performance of any other medical procedures and services that are medically recommended for a given User and currently offered by the Wellysa Application.
2.22. User – any adult natural person with full legal capacity who in any way uses the Application and/or has registered in the Application and/or has purchased the Wellysa Service, accepted the provisions of the Terms and Conditions and the Privacy Policy and/or places an order and purchases the Wellysa Service and uses the Wellysa Service in a manner not directly related to their business or professional activity.
3.1. The Wellysa service can be used by an adult, non-incapacitated person who has successfully registered an account in the Application and has purchased the Wellysa Service under the terms described in point 7 below.
3.2. The User is obliged to pay the Fee for the provision of the Wellysa Service under the terms described in point 5 below.
3.3. Upon payment of the Fees, the User concludes a Healthcare Services Agreement with NZOZ Wellysa.
4.1. The Wellysa Service, depending on the medical configuration of each service, a detailed description of which is always available in the Application before purchase, consists of all or part of the elements described below:
4.1.1. Collection of a sample (blood or other biological material) and its safe transport to NZOZ Wellysa or a laboratory performing diagnostic testing on behalf of NZOZ Wellysa,
4.1.2. Testing the sample for DNA mutations,
4.1.3. Testing the sample for concentration levels of selected medical metrics,
4.1.4. Analysis of the personal and family medical history questionnaire completed by the User in the Application,
4.1.5. Possible repeat blood test if medically indicated,
4.1.6. Possible one-time teleconsultation with a doctor if medically indicated,
4.1.7. Preparation of a Wellysa's PDF Report with analysis results, recommended follow-up tests, and recommended lifestyle.
4.2. Depending on the configuration of a given service, individual elements of the service are provided at NZOZ Wellysa, in a Laboratory, at a Collection Point, an entity providing healthcare services on behalf of NZOZ Wellysa, or at a Wellysa partner facility.
4.3. After successfully making the Payment, the User must complete their profile with additional personal data.
4.4. If the User wishes to purchase a service that includes a DNA testing component, they must consent to undergo genetic testing prior to purchase.
4.5. By purchasing any Wellysa service, the User may voluntarily consent to participate in scientific research. The rules for participation in scientific research are described in Section 6 "Consent to Scientific Research" below.
4.6. If the service purchased by the User includes a genogram analysis component, it is recommended that the User consult with family members (especially from previous generations) before completing the survey. The survey is completed after payment of the Fee. The rules for completing the survey are described in Section 7 "Family Oncology History Survey" below.
4.7. The User may voluntarily consent to receiving marketing communications to inform them about new functionalities and additional campaigns of the Wellysa Service. The communication methods are described in Section 9 "Consent to Communication" below.
4.8. Upon registration, each User receives a unique WellysaID customer number (hereinafter referred to as "WID"), which, along with any individual collection number used to complete the collection as part of the purchased service involving the collection of biological material, is used to identify the User at the Collection Point.
4.9. If the purchased service requires the donation of blood or other biological material, the User, with their WellysaID customer number, must go to one of the Blood Collection Points listed in the Application to donate blood or other material for testing.
4.10. When going to a Blood Collection Point to donate blood or other material for testing, the User must:
4.10.1. have a phone with the Wellysa app and the "Sample Collection" module enabled, allowing the selection of a Blood Collection Point and displaying their WellysaID customer number and/or the individual collection number,
4.10.2. have an ID card,
4.10.3. adhere to the preparation diet described in the Application.
4.11. At the reception desk of the Blood Collection Point, the User will be asked by an employee to provide their WellysaID customer number or present the WellysaID customer number barcode for scanning.
4.12. The User will then receive a message in the Application requesting authorization for the blood or other biological material collection procedure.
4.13. In the case of a blood collection procedure, the User declares that they are aware and acknowledge that the provision of the healthcare service involves, among other things, the collection of venous blood (approx. 5-40 ml). The blood sample will be collected via a standard needle puncture of a vein on the forearm.
4.14. The User declares that they are aware that blood collection carries a risk of the following complications/side effects:
4.14.1. Most people experience mild pain at the needle insertion site,
4.14.2. Occasionally, a small bruise may also occur.
4.15. The User declares that he or she is aware and acknowledges that significant contraindications to the provision of healthcare services in the form of blood donation include, among others:
4.15.1. blood disorders such as hemophilia or severe anemia with low hemoglobin levels,
4.15.2. active infections,
4.15.3. acute heart disease, heart attack, heart failure,
4.15.4. hemodynamic disorders such as hypotension or hypertension.
4.16. The User acknowledges that undergoing a blood collection procedure despite the above-mentioned contraindications may lead to serious health consequences, such as, among others, exacerbation of existing diseases, fainting, dizziness, or bleeding.
4.17. The User acknowledges that the obligation to obtain consent for the provision of a health service in the form of a blood collection rests with the Laboratory/Sampling Point and is implemented in accordance with the rules applicable to the given healthcare entity providing the aforementioned service.
4.18. Despite placing an Order and paying the Fee, the Center and the Laboratory will not fulfill the Health Service Agreement if the User provides data in a form that prevents the provision of health services (e.g., a fictitious name and surname or PESEL number, a mistake in the telephone number indicating that such a number is not provided). In such a case, the Fee will be refunded to the User using the same payment method used by the User.
4.19. The User consents to the provision of healthcare services in the form of all or part of the following:
4.19.1. analysis of blood test results or other biological material for the presence of DNA mutations (the detailed scope of the blood test and the measurement method used are each time specified in the Application),
4.19.2. analysis of blood test results or other biological material for the measurement of the concentrations of the tested metrics and their relationship to medical norms (the detailed scope of the blood test, together with the list of tested metrics, are each time specified in the Application),
4.19.3. analysis of information provided in the personal and family medical history questionnaire.
4.19.4. risk analysis and preparation of a preventive Wellysa's Report, containing the results of the tests, information on recommended follow-up tests, and a recommended lifestyle.
4.20. The User acknowledges that blood or other biological material collected at the Collection Point will be sent to NZOZ Wellysa, and the User will be able to review the results and recommendations after receiving the Wellysa's Report via the App.
4.21. The Wellysa's Report will be placed in the form of a PDF file or set of files in the User's account in the App. Unless the physician recommends a second blood or other biological material collection, in which case the report will be prepared after re-analysis of the collected material.
4.22. The User and NZOZ Wellysa have access to the data contained in the Wellysa's Report. With the User's consent, access to the Report may also be granted to a selected physician or physicians. Direct access to the Report or the results of another test performed as part of the Wellysa Service, after obtaining the User's prior consent, may only be granted to a physician who has an appropriate contract with NZOZ Wellysa and an account in the Wellysa system.
4.23. The Wellysa's Report, prepared by NZOZ Wellysa, determines the risk of developing serious diseases, maintaining the following risk levels:
4.23.1. high predisposition to disease
4.23.2. increased predisposition to disease
4.23.3. no signs of high predisposition to disease
4.24. If the physician preparing the analysis determines the need to repeat a blood test or other sample, the User will be notified via the App.
4.25. To repeat a blood test or other sample, the User should select a blood sample collection point from the list of available collection points in the App.
4.26. A request for a repeat blood test will be placed in the User's account in the App. Sections 4.8 - 4.18 of the Terms and Conditions apply to the repeat blood test procedure.
4.27. If a high predisposition to a disease or other medical reasons are identified, the User may be invited to a consultation with a physician. The consultation takes place via a teleconsultation (hereinafter referred to as a "Teleconsultation") via a mobile phone with the Wellysa App installed and the User's account logged in using the email address used during the account registration process. NZOZ Wellysa offers the User a choice of available teleconsultation dates via the Application.
4.28. Teleconsultation constitutes the provision of healthcare services in the form of a remote medical consultation using IT or communication systems.
4.29. At the time selected by the User in the teleconsultation module in the Application, the Physician will be ready to provide the User with a teleconsultation.
4.30. To confirm the User's identity, the physician conducting the teleconsultation will ask for basic information, such as name, date of birth, and PESEL number.
4.31. If, for unforeseen reasons, the User is unable to attend the teleconsultation at the scheduled time, the User may cancel the teleconsultation in the Application and schedule a new appointment. Cancellation of the teleconsultation is possible no later than 48 hours before the scheduled date.
4.32. In the event of an unplanned absence of the healthcare professional providing the Teleconsultation or a failure of the equipment necessary to conduct the Teleconsultation, NZOZ Wellysa will propose new dates for the Teleconsultation to the User.
4.33. NZOZ Wellysa stipulates that the recommendation to repeat a blood test or undergo a teleconsultation does not determine the specific level of risk identified, and the Wellysa physician always follows individual recommendations, acting with the utmost care and in accordance with current medical knowledge.
4.34. Each Wellysa service is described in the Application each time with a detailed scope of services from among the services described in section 2.17, as well as the deadline for each of them, if the User performs the actions indicated in the Application, e.g., scheduling a Teleconsultation in the Application.
5.1. The User is obligated to pay the Fee for the provision of the Wellysa Service.
5.2. Payment of the Fee is possible via the App, using the BLIK payment method, card payment, online payment, or payment in 3 0% installments in the Klarna system. The User's entry of a previously paid Medical Partner Code, entitling them to the provision of a specific Wellysa Service, is also considered payment of the Fee.
5.3. The Fee amount may be lower than specified in the App if the User uses a Discount Code.
5.4. The condition for payment of the Wellysa Service via the App is to submit a declaration that the provision of the Wellysa Service within 14 days of concluding the Healthcare Services Agreement results, pursuant to Article 38, paragraph 1 of the Act of 30 May 2014 on Consumer Rights, the right to withdraw from the Healthcare Services Agreement is lost upon the commencement of the Healthcare Services Agreement, at the User's request. This means that the User is not entitled to a refund of the fee paid if the User cancels the tests after the service provision process has begun, understood as the completion of the first task specified in the Application for a given medical service. This declaration is made by checking the appropriate box in the Application at the Order Summary stage, before proceeding to Payment.
5.5. After successful Payment, the User will receive the following to the email address provided in the Application: Invoice, Terms of Service of the Wellysa Service, Terms of Service, Consent to Genetic and Scientific Testing, and Privacy Policy.
5.6. The User can use the Wellysa Service immediately after the Payment is successfully processed.
6.1. After concluding the Agreement for the Provision of Services by Electronic Means, in accordance with Section 13 below, the User will be asked to voluntarily consent to participate in scientific research.
6.2. The research conducted is aimed at identifying significant medical markers, such as DNA changes, biochemical changes, changes in blood parameters, or other deviations in the materials and metrics being tested, as well as behavioral and environmental markers correlated with health, which, individually or in interaction, cause an increased risk of developing serious diseases such as cancer, heart disease, and others.
6.3. Scientific research may be conducted independently by NZOZ Wellysa or in collaboration with Scientific Partners.
6.4. The current list of scientific partners with whom scientific cooperation agreements have been concluded is:
6.4.1. Diagnostic Medicine of the Pomeranian Medical University Ltd.,
6.4.2. Hereditary Cancer Center of the Pomeranian Medical University in Szczecin,
6.4.3. Read Gene NZOZ Innowacyjna Medycyna Ltd.
6.4.4. Interhem Sp. z o.o.
6.5. Research projects in which NZOZ Wellysa is currently participating include:
6.5.1. Project "Oncological Biological Sample Bank – creation of a registry of clinical data and biological samples for genetic-clinical correlation studies." Read Gene NZOZ Innowacyjna Medycyna Ltd., in cooperation with the Hereditary Cancer Center of the Pomeranian Medical University in Szczecin and Diagnostic Medicine of the Pomeranian Medical University Ltd. z o.o., together with numerous research centers in Poland and around the world, has been conducting research on genetic and clinical correlations for many years, aimed at improving the prevention, early diagnosis, and treatment of hereditary cancers. Recent research results (publications available in the Application and the knowledge module, among others) have shown that a combined analysis of pedigree and clinical data (genogram), the occurrence of the most common DNA founder mutations in the Polish population, and measurement of element concentrations in blood are highly effective in identifying individuals at high risk of cancer.
6.6. Biological material (blood or other material) collected from individuals who voluntarily consent to participate in research studies for the purpose of providing the Wellysa Service may be stored by the Center or its Research Partners in locked rooms, with no unauthorized access. The collected tissues, identified only by a code number, will be stored in a secure location for up to 25 years. After this time, they will be destroyed, or any information that could link the samples to the patient will be completely destroyed.
6.7. NZOZ Wellysa reserves the right to destroy samples or instruct its research partner to do so for any reason, both during and after the study.
6.8. Personal data will never be disclosed, and the study results will be published anonymously.
6.9. Study participants may withdraw their consent to participate in the program at any time, which will not in any way affect the operation of the purchased Wellysa Service.
6.10. By consenting to the use of data for scientific research, the User acknowledges that the data processed in scientific projects may also be used, in an anonymous form, in other research conducted by Wellysa's Scientific Partners.
6.11. Users with additional questions regarding participation in scientific research may be directed to [email protected]
7.1. If the service purchased by the User includes a genogram analysis component, the User must complete a personal and family oncology history survey in the Application. Please note that the answers provided to the questions in the survey are essential for the proper diagnosis of medical risk and/or the appropriate diagnostic method for a given User.
7.2. If the User does not know the answers to any of the questions, the survey can be discontinued and the User should contact family members to determine the answers. If determining the answer is impossible, the User should select the "I don't know" response option in the Application.
7.3. After completing all fields of the family oncology history survey, the User will be presented with a survey summary. If any errors or omissions are identified, the User can re-edit the survey and change the incorrectly entered data or complete the missing fields.
7.4. After completing and reviewing the survey, the User submits the survey for further specialist analysis by clicking the "Send" button. Submitting the survey requires a declaration that the information provided in the survey is, to the best of the User's knowledge, correct at the time of submission. Submitting the survey for analysis is equivalent to closing any further editing.
8.1. NZOZ Wellysa is responsible for the provision of healthcare services included in the Wellysa Service and subject to the Healthcare Services Agreement concluded with the User.
8.2. Detailed principles of responsibility for the security and processing of personal and medical data are described in the document "Privacy Policy and Cookie Use for the "Wellysa" Mobile Application and the Website www.wellysa.com"
8.3. Wellysa is not liable for:
8.3.1. the provision by the User, during Registration, in the genogram, or other tests completed in the Application, of data that is inconsistent with the actual state, incomplete, or outdated,
8.3.2. any damage caused by Users' violation of third-party rights in connection with the use of the Application,
8.3.3. the consequences of third-party interception of the User's password,
8.3.4. damage resulting from disruptions in the operation of the Application or its unavailability, caused by reasons beyond Wellysa's control, or which occurred as a result of events that Wellysa was unable to prevent prevent,
8.3.5. any damage caused by the User's failure to comply with the provisions of these Terms,
8.3.6. the quality of the healthcare services provided by the Laboratory as part of the Wellysa's Service, as well as any damage resulting from the provision of healthcare services by the Laboratory,
8.3.7. the refusal to provide healthcare services as part of the Wellysa's Service by the Laboratory and any damage resulting therefrom.
9.1. The User will be asked to voluntarily consent to receiving marketing communications to inform them about new functionalities and additional campaigns of the Wellysa Service.
9.2. The User may consent to being contacted via text message and/or email and/or phone notifications.
10.1. The User has the right to withdraw from the Healthcare Services Agreement without giving a reason and at no cost, subject to the provisions below, within 14 days from the date of conclusion of the Healthcare Services Agreement, i.e., from the effective payment of the Wellysa Service Fee ("Withdrawal").
10.2. The right to withdraw from the Healthcare Services Agreement does not apply to:
10.2.1. To a User who has a Partner Code received digitally during a personal visit to a Wellysa Partner Facility, i.e., has not concluded a Distance Healthcare Agreement.
10.2.2. pursuant to Article 38, Section 1 of the Act of 30 May 2014 on Consumer Rights, due to the commencement of the Healthcare Agreement, at the User's request.
10.3. Exercising the right of withdrawal involves sending NZOZ Wellysa a declaration of withdrawal from the Healthcare Agreement. A template for the declaration is attached as Appendix 1 to the Terms and Conditions. The declaration may be sent by the User to the Center's email address - [email protected].
10.4. NZOZ Wellysa, after verifying the validity of the right of withdrawal, will immediately send the User confirmation of the declaration of withdrawal from the Healthcare Services Agreement by return email.
10.5. In the event of withdrawal from the Healthcare Services Agreement, the Agreement is deemed not to have been concluded, and the Center will immediately, but no later than 14 days from the date of receipt of the declaration of withdrawal from the Healthcare Services Agreement, refund the Wellysa Service Fee. The refund will be made using the same payment method used by the User.
11.1. The User is entitled to submit a complaint regarding the performance of the Healthcare Services Agreement.
11.2. Complaints may be submitted in the following forms:
11.2.1. electronically, to the email address of NZOZ Wellysa: [email protected]
11.2.2. in writing, to the postal address of the Center: NZOZ Wellysa, ul. Grójecka 22/24/32, 02-301 Warsaw,
11.3. It is recommended that the complaint contain at least:
11.3.1. data allowing for the identification of the User and contacting them: first and last name, email address, contact telephone number, correspondence address;
11.3.2. A description of the subject of the complaint and the circumstances giving rise to it, including the date of their occurrence;
11.3.3. A description of the User's expectations regarding NZOZ Wellysa, in particular, an indication of the desired actions on the part of NZOZ Wellysa.
11.4. The entity to which the complaint was submitted will review the complaint within 14 days of its receipt and will immediately inform the User of its review via email. If the data or information provided in the complaint requires supplementation, the entity to which the complaint was submitted will request supplementation from the complainant before reviewing it.
12.1. NZOZ Wellysa undertakes to maintain medical records in connection with healthcare services provided under the Healthcare Services Agreement concluded with the User, excluding healthcare services in the form of blood or other material collection, for which the Laboratory and the Collection Point will be responsible.
12.2. Medical records will be maintained, stored, and made available by NZOZ Wellysa and the Laboratory in accordance with the principles arising from generally applicable law, in particular the provisions of the Act of November 6, 2008, on Patients' Rights and the Patient Ombudsman, the Act of April 28, 2011, on the Healthcare Information System, and the Regulation of the Minister of Health of April 6, 2020, on the types, scope, and templates of medical records and the method of their processing.
12.3. Extracts, copies, or copies of medical records will be prepared and released at the User's request, subject to written confirmation of receipt, and in cases specified by law, also at the expense of the User requesting access to medical records.
12.4. Release of records to a third party other than the Authorized Person or the Authorized Person's statutory representative will only occur upon presentation of appropriate authorization.
13.1. The Healthcare Services Agreement is deemed concluded upon payment of the Fee by the User.
13.2. The Healthcare Services Agreement is valid until the Wellysa's Service is provided or the Wellysa's Service is refused, of which the User will be immediately informed along with the reason for the refusal.
14.1. If the User has any doubts or questions regarding the provision of the Wellysa Service, the User has the right to contact the User electronically:
14.1.1. for technical matters, regarding billing or invoices – to the email address: [email protected]
14.1.2. for medical matters, regarding the Wellysa Medical Service – to the email address: [email protected]
14.2. It is recommended that the User's questions or concerns include at least:
14.2.1. data allowing for the identification of the User and contacting them: first and last name, email address, contact telephone number, mailing address;
14.2.2. specification of the subject of the question or concern and the circumstances giving rise to it;
14.2.3. Specifying the User's expectations regarding NZOZ Wellysa, in particular, specifying the desired actions on the part of NZOZ Wellysa.
14.3. User questions or concerns submitted in accordance with this section 14.1-14.2 will be addressed promptly, but no later than 14 days from the date of their receipt, and the User will be immediately informed of their resolution via email.
15.1. In matters not regulated in these Terms, the provisions of Polish law shall apply to the relationship between the parties to the Healthcare Services Agreement, i.e., the User and NZOZ Wellysa.
15.2. The Center reserves the right to amend these Terms at any time. Amendments to these Terms are effective from the moment they are posted in the Application and apply to Healthcare Services Agreements concluded after the publication of the Terms. Healthcare Services Agreements concluded by Users before the entry into force of amendments to the Terms shall be implemented in accordance with the Terms in force at the time of conclusion of the Healthcare Services Agreement.
15.3. All disputes related to the conclusion, performance, and termination of the Healthcare Services Agreement concluded with the User shall be resolved by the competent Polish common courts.
15.4. The Appendices constitute an integral part of these Terms, i.e.
15.4.1. Appendix 1 – Sample Healthcare Services Agreement Withdrawal Form.
15.5. These Terms and Conditions come into effect on August 1, 2025.